Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples